A shorter tumor-specific survival was significantly associated with a large tumor size (HR, 1.17; 95% CI 1.04-1.32; P = 0.012), high tumor status (HR, 2.49; 95% CI 1.35-4.58; P = 0.003), lymph node involvement (HR, 4.86; 95% CI 2.93-8.04; P < 0.001), solid predominant with mucin production adenocarcinoma (HR, 1.82; 95% CI 1.07-3.07; P = 0.026), and no adjuvant therapy (HR, 0.06; 95% CI 0.03-0.12; P <.001). Here, MUC5AC is linked to neoplasm.